Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1619856 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $1.51Day +2.72%Mkt cap $150M1Y −26.3%Off 52W high −57.3%Vol (1Y) 74.7%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,256 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest11.7% of sh out |
| Days to cover4.9d |
| 13F net flow (QoQ)+0.74% |
| Top-10 13F concentration58.8% |
| Next report (est.)2026-08-07 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$11.2M |
| Earnings (TTM)-$133.2M |
| ROE−79.0% |
| Net margin−1327.4% |
| ROIC−67.6% |
| Sales growth 3Y−7.0% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−5.0% |
| 1Y−26.3% |
| 3Y−79.0% |
| 5Y−90.7% |
| Since incept. (ann.)−38.1% |
Total return through 2026-07-30 · series begins 2021-07-26. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)74.7% |
| Ann. volatility (3Y)82.5% |
| Sharpe (1Y)0.02 |
| Sharpe (3Y)−0.22 |
| Max drawdown (1Y)−51.1% |
| Max drawdown (3Y)−91.1% |
| Beta (3Y vs SPY)3.11 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Pfizer Inc | 4.7M | $8M | 4.85% | +0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.8M | $7M | 3.90% | new |
| RENAISSANCE TECHNOLOGIES LLC | 2.6M | $5M | 2.68% | +58.0% |
| Kynam Capital Management, LP | 2.5M | $5M | 2.59% | +0.0% |
| BlackRock, Inc. | 2.1M | $4M | 2.22% | +0.1% |
| TWO SIGMA INVESTMENTS, LP | 1.8M | $3M | 1.82% | +72.5% |
| BANK OF AMERICA CORP /DE/ | 1.3M | $2M | 1.34% | +30.6% |
| Aberdeen Group plc | 1.2M | $2M | 1.25% | −12.7% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$0.26 | — | $2.4M | +1.9% |
| 2025-12-31 | 2026-03-05 | — | — | $3.9M | +89.7% |
| 2025-09-30 | 2025-11-12 | −$0.30 | — | $2.2M | +8.6% |
| 2025-06-30 | 2025-08-12 | −$0.58 | — | $2.7M | −23.0% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-07 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
